Loading...
Loading...
REGN| Name | Value |
|---|---|
| Revenues | 3,720.7M |
| Cost of Revenue | 491.1M |
| Gross Profit | 3,229.6M |
| Operating Expense | 2,050.1M |
| Operating I/L | 1,179.5M |
| Other Income/Expense | 313.5M |
| Interest Income | 187.4M |
| Pretax | 1,493.0M |
| Income Tax Expense | 152.4M |
| Net Income/Loss | 1,340.6M |
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical company that focuses on discovering, inventing, developing, and commercializing medicines for various diseases. The company's products include EYLEA for eye conditions, Dupixent for dermatitis and asthma, Libtayo for skin cancer, Praluent for cholesterol management, and REGEN-COV for covid-19. Additionally, it offers treatments for rheumatoid arthritis, infectious diseases, and cancer. Regeneron also collaborates with several pharmaceutical companies and has agreements with government agencies and other biotech firms to develop and commercialize new products. The company generates revenue through the sale of its pharmaceutical products and through collaboration and licensing agreements.
